Announcement 26 April 2022
The FleurirABX team presented two posters at the 2022 European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) meeting held in April 2022 in Lisbon, Portugal.
One poster summarized studies conducted by FleurirABX on a wide range of gram-negative pathogens, entitled “In-vitro activity of a fosfomycin-trimethoprim-sulfamethoxazole combination against 3rd-generation cephalosporin, beta-lactam-beta-lactamase inhibitor combination, carbapenem, aminoglycoside, tigecycline, polymyxin B, and/or colistin-resistant Escherichia coli, Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumanniiclinical isolates.”
The second poster summarized studies conducted by FleurirABX on a wide range of gram-positive pathogens, entitled “In-vitro activity of a fosfomycin-trimethoprim-sulfamethoxazole antibacterial combination against methicillin-resistant Staphylococcus aureus and Enterococcus spp.”
FleurirABX is a privately-held pre-clinical biotechnology company that has been actively developing a combination of fosfomycin and co-trimoxazole. The company has been issued patents covering the unique antibacterial synergy of any fosfomycin and any sulfamethoxazole and any diaminopyridine in combination, including the fosfomycin/ co-trimoxazole synergistic combination, from the US Patent office (Patent Number 15/527,705), European Patent office (EP Appl. No. 15860075.9), and Taiwan Patent Office (Patent Number 104138153). The fosfomycin/co-trimoxazole combination has potential for broad clinical utility, including but not limited to UTI, ABSSSI, and drug-resistant respiratory tract infections.